Study of Rule-Based Algorithms in Anemia Management in Prevalent Hemodialysis Patients and Its Relation to Patients' Outcomes
1 other identifier
interventional
145
1 country
1
Brief Summary
The study will assess role of rule based algorithm in anemia management in hemodialysis patients and its relation to patient's mortality
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for phase_1
Started Jan 2025
Shorter than P25 for phase_1
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2025
CompletedFirst Submitted
Initial submission to the registry
May 6, 2025
CompletedFirst Posted
Study publicly available on registry
May 30, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 30, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
June 30, 2025
CompletedMay 30, 2025
January 1, 2025
6 months
May 6, 2025
May 21, 2025
Conditions
Outcome Measures
Primary Outcomes (1)
Increase the number of patients in the target Hb range
This study will achieve better dosing of erythropoietin stimulating agents using rule based algorithms to correct anemia and avoid unnecessary extra doses of erythropoietin stimulating agents with their side effects
6 months
Study Arms (1)
end stage renal disease patients
EXPERIMENTALmanagement of different hemoglobin levels by erythropoietin stimulating agents according to expert opinion and according to algorithm
Interventions
anemia management algorithm will successfully increase the number of patients in the target hemoglobin range
Eligibility Criteria
You may qualify if:
- patients on hemodialysis for more than six months patients undergoing hemodialysis three times per week each session for 4 hours patients with urea reduction ratio\>65% patients with transferrin saturation\>20%
You may not qualify if:
- patients with terminal illness or malignancy patients receiving hemodialysis from catheter or arteriovenous graft
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Hemodialysis Units in Ain Shams University Hospitals
Cairo, Egypt
Study Design
- Study Type
- interventional
- Phase
- phase 1
- Allocation
- NA
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
May 6, 2025
First Posted
May 30, 2025
Study Start
January 1, 2025
Primary Completion
June 30, 2025
Study Completion
June 30, 2025
Last Updated
May 30, 2025
Record last verified: 2025-01
Data Sharing
- IPD Sharing
- Will not share